Latest News
Latest News
What are the risk factors for Mohs surgery–related anxiety?
“Routinely recommending consultations may not be the best approach for improving anxiety outcomes,” the study authors wrote.
Feature
High cost and demand for old cancer drug sparks crisis
Experts have voiced alarm at the scarcity and cost of fludarabine, an old drug deemed crucial to cellular therapy for leukemia.
News
FDA approves olutasidenib for some AML patients
Olutasidenib has been green-lighted by the FDA for treatment of some patients with acute myeloid leukemia.
Latest News
Deductibles a threat to more imaging after abnormal mammogram
The ACA does not mandate coverage for additional tests and a biopsy to help determine whether the patient has cancer.
Latest News
Women docs: How your next job contract can reflect your real goals
“I found that navigating contracts from the standpoint of a woman still in childbearing years was a little disappointing and challenging,”
Latest News
Pandemic caused treatment delay for half of patients with CTCL, study finds
No clinical trials exist to inform maintenance protocols in patients with cutaneous lymphomas.
Latest News
Who’s more likely to develop a second primary melanoma?
"High numbers of nevi and high genetic predisposition were more strongly associated with second [rather] than first primary melanomas."
Feature
How blunt is too blunt for informed consent?
There’s a fine line between providing enough information on the risks and benefits of a particular treatment and knowing you’ve explained it well...
From the Journals
Analysis of doctors’ EHR email finds infrequent but notable hostility
Researchers were struck by the hostility of negative sentiment in some emails to physicians.
From the Journals
Doctor urges compassionate access to specialized radiotherapy for inoperable RCC
SABR should be considered for patients with larger, inoperable kidney cancers who have no treatment options.
From the Journals
U.S. biosimilar competition, use, and availability still lags behind European countries
Greater marketing and uptake of biosimilars in Germany and Switzerland promoted lower drug costs, compared with the United States.